Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd

Dajia Weikang released its 2026 half-year report. First-half net profit attributable to the parent was 7.26 million yuan, up 712.1% year on year. Operating revenue was 2.702 billion yuan, down 0.2% year on year. Net profit attributable to the parent after deducting non-recurring items swung from a loss of 720,000 yuan in the same period last year to a profit of 8.47 million yuan. Net operating cash flow was 11.47 million yuan, up 107.4% year on year. Earnings per share were 0.04 yuan. In the second quarter, operating revenue was 1.32 billion yuan, down 6.5% year on year, and net profit attributable to the parent swung from a loss of 2.25 million yuan in the same period last year to a profit of 1.29 million yuan. As of the end of the second quarter, total assets were 6.33 billion yuan, down 0.1% from the end of the previous year, and net assets attributable to the parent were 1.495 billion yuan, up 0.5%. The company said in the half-year report that the pharmaceutical distribution industry continues to develop amid trends toward standardization, consolidation, and digitalization. The company will deepen the integrated operation of intelligent warehousing hardware and digital supply chain systems, transform into a comprehensive supply chain service provider, and continue to expand in specialty pharmacies and health management.